drugset / Trial / NCT00332657
Anecortave Acetate Risk Reduction Trial (AART)
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.
Timeline
- Start
- 2006-09
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anecortave Acetate | Small molecule | 15 mg | Other |
| Subject | Anecortave Acetate | Small molecule | 30 mg | Other |
Indications
No indication recorded.